[Notes on the more effective fibrinolytic effect of nicotinic acid in an extemporaneous drug association].
D000255:Adenosine Triphosphate / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000150:complications*; D001205:Ascorbic Acid / Q000627:therapeutic use*; D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007294:Inositol / Q000627:therapeutic use*; D009539:Nicotinic Acids / Q000627:therapeutic use*; D013927:Thrombosis / Q000517:prevention & control*
D005343:Fibrinolytic Agents; D009539:Nicotinic Acids; D007294:Inositol; D000255:Adenosine Triphosphate; D006493:Heparin; D001205:Ascorbic Acid
Appunti sul miglior effetto fibrinolitico dell'acido nicotinico in una estemporanea associazione medicamentosa.